Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results And Key Operational And Financial Highlights
8/8/2014 9:13:08 AM
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced financial results and recent key operational and financial highlights for the three and six months ended June 30, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by